Evidence map›Paper›PMID 40405095›Full record

ArticleBMC cancer2025

Evaluation and implementation of multidisciplinary, standardized, guideline-based long-term follow-up care for adult survivors of childhood cancer in Germany: protocol of a prospective, multi-center, nationwide study (LE-Na).

C Cytera, K Baust, A Borgmann-Staudt, G Calaminus, K Egger-Heidrich, J Faber, D Grabow, T Halbsguth, A Kock-Schopenhauer, I R König and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

C CyteraPaediatric Haematology and Oncology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
K BaustDepartment for Paediatric Haematology/Oncology, University Hospital Bonn, Bonn, Germany.
A Borgmann-StaudtDepartment of Paediatric Oncology and Haematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
G CalaminusDepartment for Paediatric Haematology/Oncology, University Hospital Bonn, Bonn, Germany.
K Egger-HeidrichDepartment of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany.
J FaberDepartment of Pediatric Hematology, Oncology, and Hemostaseology, Center for Pediatric and Adolescent Medicine, University Medical Centerof the, Johannes Gutenberg-University Mainz , Mainz, Germany.
D GrabowDivision of Childhood Cancer Epidemiology / German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Centreof the, Johannes Gutenberg University Mainz , Mainz, Germany.
T HalbsguthMedical Clinic II, Haematology and Oncology, University Hospital Frankfurt Am Main, Frankfurt Am Main, Germany.
A Kock-SchopenhauerInstitute of Medical Biometry and Statistics, Section for Clinical Research IT, University of Luebeck and University Hospital Schleswig-Holstein, Luebeck, Germany.
I R KönigInstitute of Medical Biometry and Statistics, University of Luebeck, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
S MichaelisDepartment of Paediatric Oncology and Haematology, University Hospital Tübingen, , Tübingen, Germany.
A NeumannInstitute of Medical Biometry and Statistics, Section for Clinical Research IT, University of Luebeck and University Hospital Schleswig-Holstein, Luebeck, Germany.
A PuzikDivision of Paediatric Haematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
S SchusterDepartment of Paediatric Haematology and Oncology, University Hospital Erlangen, Erlangen, Germany.
F WoltersII.Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
C ArendtPaediatric Haematology and Oncology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
M SleimannDepartment of Paediatric Oncology and Haematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health, Berlin, Germany.
T LangerPaediatric Haematology and Oncology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
J GebauerDepartment of Internal Medicine I, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. judith.gebauer@uksh.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLate effects can occur years to decades after cancer therapy, resulting in morbidity and reduced health-related quality of life. Clinical long-term follow-up (LTFU) enables timely diagnosis and treatment of these sequelae. So far, only a minority of childhood cancer survivors (CCS) in Germany regularly visit LTFU care facilities. The LE-Na study aims to: 1. implement and/or improve LTFU care structures for adult CCS in Germany, 2. inform former patients about late effects and LTFU care centers, 3. create a basis for future research by building up a central database, consent management and infrastructure, 4. establish a clinical LTFU cohort of adult CCS in Germany, 5. evaluate the implementation of the LFTU care, 6. enable the expansion of LTFU care structures nationwide, 7. integrate the developed LTFU care structures into the standard health care system.

methodsWithin five years, approximately 5000 CCS will be invited to visit one of the 10 LTFU centers in Germany. Study participants are either contacted by the German Childhood Cancer Registry (GCCR), transitioned from the local pediatric oncology care unit, or recruited via media. They are assigned to one of three different risk groups based on an evidence-based risk stratification and receive standardized multidisciplinary follow-up care. Primary outcomes are satisfaction with the LTFU care offer as well as degree of health-related self-efficacy expectation. They will be assessed at two time points. A scientific evaluation of the implemented LTFU care will be enabled by a waitlist control group. The harmonized outcome data are documented in a standardized database. DISCUSSION: By addressing CCS in Germany who have not received standardized LTFU care yet, the LE-Na study expects to improve nationwide LTFU care and therewith patient's satisfaction with the LTFU care offer as well as their health-related self-efficacy expectation.

Indexed as

AftercareCancer SurvivorsNeoplasmsAdolescentAdultChildFemaleFollow-Up StudiesGermanyHumansMaleMulticenter Studies as TopicPractice Guidelines as TopicProspective StudiesQuality of LifeYoung AdultChildhood cancer survivorsLate effectsLong-term follow-up

Identifiers

PMID40405095
PMCPMC12100823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.